Please login to the form below

Not currently logged in
Email:
Password:

Keytruda

This page shows the latest Keytruda news and features for those working in and with pharma, biotech and healthcare.

Merck & Co reveals plans for women’s health spinoff Organon

Merck & Co reveals plans for women’s health spinoff Organon

namely blockbuster checkpoint inhibitor Keytruda (pembrolizumab) – but will also “enable necessary investments”.

Latest news

More from news
Approximately 161 fully matching, plus 274 partially matching documents found.

Latest Intelligence

  • Putting commercial intelligence at the heart of strategy Putting commercial intelligence at the heart of strategy

    Merck Sharp &Dohme (MSD), the company that markets Keytruda, and Bristol-Myers Squibb (BMS), the company that markets Opdivo, approached development of their respective products in this area with starkly contrasting

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Opdivo is being squeezed out of the market by Merck &Co/ MSD’s Keytruda (pembrolizumab), which dominates the lucrative first-line NSCLC market and is cutting into BMS’ share of the ... Trial results for Opdivo alongside CTLA4 checkpoint inhibitor

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    its role in developing immuno-oncology blockbuster Keytruda. ... The coming Keytruda windfall will also allow the charity to set up a stand-alone venture capital division, with which it could seed funding and help promote research in key areas.

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast. ... On 28 December, Keytruda gained FDA clearance for use in Merkel cell carcinoma.

More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....